SRI SIDDHARTHA ACADEMY OF HIGHER EDUCATION

(DEEMED TO BE UNIVERSITY)

Declared under Section 3 of the UGC Act, 1956, MHRD *GOI No. F.9-31/2006-U.3 (A) Dated: 30/05/2008*

Accredited 'A' Grade by NAAC

Agalakote, B.H.Road, Tumkur – 572 107.KARNATAKA, INDIA.

Ph. 0816- 2275516, Fax : 0816-2275510 website: sahetumkur.ac.in email: info@sahe.in

e-copies of grants awarded for clinical trails

Name of researcher	Granting agency	Letters	
Dr Jagannath	JSS medical research India Pvt. ltd	Clinical Trial Agreement and Insurance Policy	View Document
Dr. Kiran Kallaiah	SMO Clinical Research India Pvt. ltd	Clinical Trial Agreement and Insurance Policy	View Document

S.S.A.H.E TUMKUR

REGISTRAR
Sri Siddhartha Academy of Higher Education
Agalakote, B.H. Road, Tumkur - 572 107.

INDIA NON JUDICIAL

Government of National Capital Territory of Delhi

e-Stamp

सत्यमेव जयते

Certificate No.	:	**IN-DL86023031682093R**
Certificate Issued Date	:	21-Nov-2019 12:35 PM
Account Reference	:	IMPACC (IV)/ dl988103/ DELHI/ DL-DLH
Unique Doc. Reference	:	SUBIN-DLDL98810380834959198473R
Purchased by	:	JSS MEDICAL RESEARCH INDIA PVT LTD
Description of Document	:	Article 5 General Agreement
Property Description	:	Not Applicable
Consideration Price (Rs.)	:	0 (Zero)
First Party	:	JSS MEDICAL RESEARCH INDIA PVT LTD
Second Party	:	SRI SIDDHARTHA MEDICAL COLLEGE TUMKUR KARNATAKA
Stamp Duty Paid By	:	JSS MEDICAL RESEARCH INDIA PVT LTD
Stamp Duty Amount(Rs.)	:	100 (One Hundred only)

Home

Please write or type below this line

DATED 20 NOV 2019
JSS MEDICAL RESEARCH INDIA PRIVATE LIMITED
(AS THE CONTRACT RESEARCH ORGANIZATION AS ("CRO")
AND
DR. JAGANNATH (AS THE PRINCIPAL INVESTIGATOR)
PROFESSOR AND HOD, DEPARTMENT OF SURGERY
SRI SIDDHARTHA MEDICAL COLLEGE
AND
DR. A.G. SRINIVAS MURTHY (AS THE SITE/INSTITUTION)
DEAN AND PRINCIPAL
SRI SIDDHARTHA MEDICAL COLLEGE AND
RESEARCH CENTRE, B H ROAD, AGALKOTE,
TUMKUR, KARNATAKA-572107, INDIA
AND
MS. SUDHA RAJ (AS THE SMO)
CLINISYD RESEARCH GLOBAL SOLUTIONS PVT LTD
#1/1 KRISHNANDNAGAR, NAGARABHAVI
BANGALORE - 560 091, KARNATAKA, INDIA

CLINICAL TRIAL AGREEMENT

Sree Siddhartha Medical College & Hospital No ---- Date ---- TUMKUR-7

JSS Medical Research India Pvt. Ltd. Faridabad

Statutory Alert:
1. The authenticity of this Stamp Certificate should be verified at "www.shcilestamp.com". Any discrepancy in the details on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

Scanned by CamScanner

This Clinical Trial Agreement (the "**Agreement**") dated 20 Nov 2019

BETWEEN:

1. **JSS Medical Research India Private Limited.,** a company registered under the provisions of Indian Companies Act, 1956, having Corporate Identification Number (CIN) U74999DL1999PTC102149 and its office at 12/2, 6th Floor, Tower-B, Vatika Mindscapes, Sector 27-D, Faridabad-121003, Haryana, India acting through its authorized signatory Dr. Renu Razdan, Senior Vice President, (hereinafter referred to as "**JSS India**" which expression shall mean and include unless repugnant to the context, its successors and permitted assigns).

And

2. Dr. Jagannatha working as a Professor and HOD, Department of Surgery at Sri Siddhartha Medical college having his residence at Sri Siddhartha Medical College, B.H. Road, Agalkote, Tumakuru, Karnataka 572107 (hereinafter referred to as the "**PI**").

And

3. Sri Siddhartha Medical College a hospital registered under the provisions of [Indian Companies Act, 1956 OR *any other relevant law*], having its registered office at B.H. Road, Agalkote, Tumakuru, Karnataka 572107 being authorized to sign this Agreement (hereinafter referred to as the "**Site**" which expression shall mean and include unless repugnant to the context, its successors and permitted assigns).

And

4. CLINISYd Research Global Solutions Pvt Ltd (Site management service provider) having its registered office at #1/3, Krishnanadnagar, Nagaravhavi 2nd stage, Bangalore-560090, being authorized to sign this Agreement (hereinafter referred to as the "**SMO**" which expression shall mean and include unless repugnant to the context, its successors and permitted assigns).

JSS India, the PI, and the Site are collectively referred to as "*Parties*" and also individually referred to as "*Party*" where the context so necessitates.

Whereas:

A. JSS India is a Contract Research Organization (CRO) and is in the business of providing Clinical Trial Site Management Services, Clinical Trial Monitoring Services and Clinical Data Management Services and certain other services related to any clinical study including site and principal investigator identification, regulatory, pharmacy services, identification and management of other agencies related to a clinical study translation of documents.

B. The Site is engaged in treatment of patients & conducting clinical trials and the PI is Dr. Jagannath, Professor and HOD, Department of Surgery at the Site.

C. NovaLead Pharma Private Limited is the Sponsor, desires to conduct a clinical trial titled- 'A prospective, multicenter, randomized, double-blind, phase 3 study to evaluate the safety and efficacy of a gel formulation of Esmolol Hydrochloride (Galnobax®) in treating

20/11/19 20/11/19

Sree Siddhartha Medical College & Hospital No Date TUMKUR-7

JSS Medical Research India Pvt. Ltd. Faridabad

Scanned by CamScanner

प्रधान मुद्रांक कार्यालय, मुंबई के प्रमाणीकरण पत्र क्रमांक सी.एस.डी. /76/2018/2730-31/17 दिनांक 17/07/2018 के अनुसार एकत्रित बीमा मुद्रांक शुल्क ₹ 1/- भुगतान किया गया है।

THE NEW INDIA ASSURANCE CO. LTD.
D. O. 111200, NEW INDIA BHAVAN
34/38 BANK STREET FORT, MUMBAI – 400 023.
Forming Part of Policy No: 111200361905000000024

Policy Document

Insured	CRO: JSS Medical Research India Pvt. Ltd Sponsor: NovaLead Pharma Pvt. Ltd Permanent/Temporary/Contract/Apprentices of the above (Including Medical Doctors / Hospitals) Ethics Committee and its members
Policy Type	Clinical Trial Policy
Policy Number	111200361905000000024
Period of Insurance	From 00:00 on 04.01.2020 to Midnight of 03.01.2021
Retroactive Date	04.01.2019
Limit of liability	INR 5 Cr AOA: AOY 1:1 • Medical Payment Coverage: Sub limit to INR 15 lacs per subject • On event of death: Sub limit to INR 75 lacs per subject
Territory	India Only
Deductibles	INR 50,000 for each and every claim
Covers	• Extended Reporting period : 3 months • Defence costs within limits of Insurance. • Settlement with mediation – consent of insurer is mandatory • Coverage for any claims recommended by CDSCO subject to per patient limits. • Coverage is extended to include negligent act, error or omission of the Insured in rendering or failure to render medical professional services which results or may result in bodily injury or death to research subject participating in the trial
Study Title	Protocol Number: NG-A16 A Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study To Evaluate The Safety And Efficacy Of A Gel Formulation Of Esmolol Hydrochloride (Galnobax®) In Treating Diabetic Foot Ulcers

Scanned by CamScanner

THE NEW INDIA ASSURANCE CO. LTD.
D. O. 111200, NEW INDIA BHAVAN
34/38 BANK STREET FORT, MUMBAI – 400 023.
Forming Part of Policy No: 111200361905000000024

CT details	Subjects: 350 Study duration: 25 Weeks Study Location: 51 Centres in India Study Phase: Phase 3
Subjectivities	This quote is subject to signed mandate, pan card copy of the client and GST certificate of the client at the time of placing the business

For The New India Assurance Co Ltd.

AUTHORISED SIGNATORY

Scanned by CamScanner

सत्यमेव जयते

INDIA NON JUDICIAL

Government of Karnataka

Rs. 100

e-Stamp

Certificate No.	:	IN-KA67852431586059T
Certificate Issued Date	:	06-Aug-2021 10:41 AM
Account Reference	:	NONACC (FI)/ kacrsfl08/ MALLESHWARAM1/ KA-BA
Unique Doc. Reference	:	SUBIN-KAKACRSFL0898441826839511T
Purchased by	:	SMO CLINICAL RESEARCH INDIA PVT LTD
Description of Document	:	Article 12 Bond
Description	:	CLINICAL STUDY AGREEMENT
Consideration Price (Rs.)	:	0 (Zero)
First Party	:	SMO CLINICAL RESEARCH INDIA PVT LTD
Second Party	:	SRI SIDDHARTHA MEDICAL COLLEGE AND Dr KIRAN K
Stamp Duty Paid By	:	SMO CLINICAL RESEARCH INDIA PVT LTD
Stamp Duty Amount(Rs.)	:	100 (One Hundred only)

Home

सत्यमेव जयते

Authorised Signatory
State Registration & Stamps Department
Malleshwaram Branch

SMO CLINICAL RESEARCH INDIA PVT LTD IN-KA67852431586059T RS. 100 06-AUG-2021 10:41 AM

Please write or type below this line

CLINICAL STUDY AGREEMENT

1. SMO CLINICAL RESEARCH (I) PVT LTD ,(SMO-India) a Contracted Research Organization company incorporated under the laws of India, having its Registered Office at #461, 11th Main, Sadashiva Nagar, RMV Extension, Bangalore-560080, Karnataka, India, (hereinafter referred to as "the CRO")

Statutory Alert:
1. The authenticity of this stamp certificate should be verified at 'www.shcilestamp.com' or using e-Stamp Mobile App of Stock Holding. Any discrepancy in the details on this Certificate and as available on the website / Mobile App renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

GOVERNMENT OF KARNATAKA GOVERNMENT OF KARNATAKA GOVERNMENT OF KARNATAKA GOVERNMENT OF KARNATAKA GOVERNMENT OF KARNATAKA GOVERNMENT OF KARNATAKA

Scanned with OKEN Scanner

Among

1. **SMO CLINICAL RESEARCH (I) PVT LTD ,(SMO-India)** a Contracted Research Organization company incorporated under the laws of India. having its Registered Office at #461, 11th Main, Sadashiva Nagar, RMV Extension, Bangalore-560080, Karnataka, India, (hereinafter referred to as **"the CRO"**)

2. **Dr. Kiran Kallaih** with his principal office located at Sri Siddhartha Medical College and Research Centre, B H Road Agalkote, Tumkur, 572107, Karnataka, India (here in after referred to as "Principal Investigator")

3. **Sri Siddhartha Medical College and Research Centre** having its Registered office at, B H Road Agalkote, Tumkur, 572107, Karnataka, India (hereinafter referred to as "the Institution")

JC ORTHOHEAL PROJECT:

This Clinical Study Agreement ("Agreement") is executed on 23rd day of July, 2021 ("Effective Date") among **SMO CLINICAL RESEARCH (I) PVT LTD** , a Contracted Research Organization company incorporated under the laws of India, having its Registered Office at #461, 11th Main, Sadashiva Nagar, RMV Extension, Bangalore-560080, Karnataka, India **Dr. Kiran Kallaih at Sri Siddhartha Medical College and Research Centre, B H Road Agalkote, Tumkur, Karnataka 572107** For the study entitled **Protocol: FlexiOH®**: *A Prospective, Openlabel, Randomized, Clinical Trial Of Light Cured Limb Orthosis - FlexiOH® as Definitive Cast For Immobilization Of Forearm Fractures In Emergency Settings* related to the device known as FlexiOH® –Short Arm Cast **("Study Device")** in accordance with the Protocol ID **"OH/SMO/01/2021" ("Protocol")** belonging to "JC OrthoHeal Pvt Ltd " **("SPONSOR").** (Here in after referred to as **"the study"**).

THE PARTIES AGREE AS FOLLOWS:

1. The Sponsor would like to test the **FlexiOH® –Short Arm cast** namely **Investigational Medical Device** which will be used in **patients with displaced fracture of distal end of radius and/or ulna.** The SPONSOR/ CRO hereby declares that all the necessary permissions and licenses required under the provisions of relevant Acts and Rules namely Medical Device Rules 2017, Declaration of Helsinki, the Indian Guidelines on Good Clinical Practices, ISO 14155 and applicable laws, rules and regulations will be obtained before the start of the study.

2. The SPONSOR/CRO have approached the Investigator as they desire to perform the study in regards to the said device in accordance with the Declaration of Helsinki, the Indian Guidelines on Good Clinical Practices and Local Regulations and have accordingly finalized the Clinical Trial Protocol.

Scanned with OKEN Scanner

5. **Funding:** The conduct of the study will not impose any financial burden on the Principal Investigator or the Institution. The SPONSOR /CRO declare to bear all the expenses pertaining to the conduct of the study.

   5.1 **Financial Support for Clinical Trial:** The details of the financial support to investigators and the budget sheet are attached in Annexure A hereunder:

6. **Protocol:** Investigator will conduct the Study in accordance with the Protocol, Indian GCP guidelines, ISO 14155 and applicable rules and regulations in India.

   6.1 **Amendments:** The Protocol may be modified only by a written Amendment, signed by both the SPONSOR/CRO and the Principal Investigator.

   6.2 **Emergency Amendments**: If it is necessary to change the Protocol on an emergency basis for the safety of the subjects, Investigator will notify the SPONSOR ,CRO and the responsible Independent Ethics Committee or Institutional Review Board (as applicable) as soon as practicable but, in any event, not later than five working days after the change is implemented. Any emergency change to the Protocol must be followed by execution of a written Amendment within **30** days.

7. **Subject Enrolment:** Investigator has agreed agrees to enrol the subjects in the study as may be defined and decided by the SPONSOR/CRO from time to time. A qualified subject is one who meets all Protocol criteria such as inclusion & exclusion criteria and agrees to participate in the study through informed consent in writing.

   7.1 **Excess Enrolment:** If Investigator enrols the maximum number of qualified subjects, the SPONSOR/CRO may or may not invite Investigator to enrol additional subjects. However, the Principal Investigator shall not enrol more than maximum number without prior approval by the SPONSOR.

   7.2 **Failure to Enrol:** If Investigator fails to enrol subjects at a rate adequate to meet the enrolment requirement, the SPONSOR/CRO shall be free to terminate the Study early (see Section 23, Termination).

8. **Study Conduct:** Investigator will conduct Study in accordance with the Protocol, the Sponsor's written instructions, Indian Good Clinical Practices (Indian GCP) guidelines and all applicable governmental laws, rules, and regulations.

   8.1 **No Charge for Investigational Device or Reimbursed Services:** Investigator will not charge a Study subject or third-party payer for Investigational Device (see Clause 13.1, Investigational Device) or for any services reimbursed by the SPONSOR under this Agreement.

9. **Independent Ethics Committee/Institutional Review Board:** Before the Study is initiated, Investigator will ensure that both the Study and the informed consent form are approved by an Independent Ethics Committee or Institutional Review Board (as applicable) (both referred to as a 'IRB') that complies with all applicable laws and

Scanned with OKEN Scanner

regulations. Investigator will further ensure that the Study is subject to continuing oversight by the IRB throughout its conduct.

10. **Study Disapproval:** If, through no fault of Investigator, the Study is disapproved by the IRB, this Agreement will immediately terminate with no penalty to the Investigator, as provided in Section 23.1.1, Disapproval by IRB, below.

11. **Data Protection:** Data collected in Study may include personal data and sensitive information which is subject to specific legislation relating to the processing, storage, transfer and use of such data or information. The Investigator will comply with all relevant laws relating to the protection and use of personal data and data privacy in its conduct and reporting of the Study. The Investigator shall take all technical and organizational measures to prevent unauthorized or unlawful processing or accidental loss or destruction of, or damage to, or disclosure of such data. THE SPONSOR/CRO will take appropriate measures to protect the confidentiality and security of all personal data that it receives from Investigator in connection with the Study. Personal data relating to the Investigator shall be processed and used for the purposes of administration of this agreement and in connection with the Study and will be held on one or more databases for the purposes of determining the Investigator's involvement in future research and in order to comply with any regulatory requirements.

12. **Informed Consent and Authorization to Use and Disclose Health Information:**

    12.1 Informed Consent: Investigator will obtain a written informed consent from each Study subject and will maintain a signed original of that consent in the subject's record. Investigator will allow the SPONSOR/CRO to inspect signed informed consent forms or photocopies thereof during monitoring visits or audits (see Monitoring and Audits, Section 16).

13. **Adverse Events:** Investigator will report adverse events experienced by Study subjects in accordance with instructions in the Protocol and applicable regulations. This includes, where required, prompt reporting by telephone, e-mail or facsimile. The Investigator shall, so far as is lawful, have full responsibility for the reporting of all serious and unexpected adverse events and/ or deaths to local regulatory authorities as per prevailing regulations. The SPONSOR/CRO has and will maintain during the Study, an insurance policy adequate to cover adverse events or injury to Study Subject(s) as a direct result of participation in the Study.

    13.1 Investigational Device: The SPONSOR will provide Investigator with sufficient quantities of the investigational device(s) needed to conduct the Study.

    13.2 Custody and Dispensing: The Principal Investigator will maintain appropriate control of supplies of Investigational Device and will not provide it to anyone else except sub-investigators or research staff. The Principal Investigator shall maintain the records of inventory of the Investigational device.

Scanned with OKEN Scanner

13.3 Use: Investigator will use Investigational Device only as specified in the Protocol. Any other use of Investigational Device constitutes a material breach of this Agreement.

13.4 Ownership of Investigational device: Investigational device remains the property of the Sponsor except for, and limited to, the use specified in the Protocol, the Sponsor/CRO grants Investigator no express or implied intellectual property rights in Investigational device or in any methods of making or using the SPONSOR's DEVICE.

14. Confidential Information: During the course of the Study, Investigator may receive or generate information that is confidential to the SPONSOR/CRO. Any information marked by the SPONSOR/CRO as confidential and provided to the investigator 1 year before the execution of this agreement will also be treated as confidential information.

14.1 Definition: Except as specified in Section 14.2, Exclusions, below, "Confidential Information" includes

14.1.1 the Protocol,

14.1.2 the Investigator Brochure,

14.1.3 Study Data (as defined in Section 15, Study Data, and Study Records, below), subject to

14.1.4 Investigator's right to publish the results of the Study (as described in Section 18, Publications, below),

14.2 Exclusions: Confidential Information does not include information that

14.2.1 is known or open to the public or otherwise in the public domain at the time of disclosure,

14.2.2 becomes part of the public domain during the term of this confidentiality obligation by any means other than breach of this Agreement by Investigator,

14.2.3 is already known to Investigator at the time of disclosure and is free of any obligations of confidentiality, or

14.2.4 Is obtained by Investigator, free of any obligations of confidentiality, from a third party that has a lawful right to disclose it.

14.3 Obligations of Confidentiality: Unless the SPONSOR/CRO provides prior written consent, Investigator may not use Confidential Information for any purpose other than that authorized in this Agreement, nor may Investigator disclose Confidential Information to any third party except as authorized in this Agreement or as required by law.

14.3.1 Required disclosure of Confidential Information to the IRB or to regulatory representatives is specifically authorized.

14.3.2 Publication of the results of the Study based on Study Data collected or generated by Investigator is specifically authorized, subject to the provisions of Section 18, Publications, of this Agreement.

Scanned with OKEN Scanner

14.4 **Disclosure Required by Law:** If disclosure of Confidential Information to any party other than the IRB relevant regulatory authority is required by law, that disclosure does not constitute a breach of this Agreement so long as Investigator

14.4.1 Notifies the Sponsor in writing in 15 working days advance of the disclosure so as to allow the Sponsor to take legal action to protect its Confidential Information,

14.4.2 Discloses only that Confidential Information required complying with the legal requirement, and

14.4.3 Continues to maintain the confidentiality of this Confidential Information with respect to all other third parties.

14.5 **Individually Identifiable Health Information:** If, in connection with this Study or performance of this Agreement, the Sponsor/CRO comes into contact with individuality identifiable health information relating to subjects who are not Study subjects, the SPONSOR/CRO agrees to maintain the confidentiality of such information and not to use it for any purpose.

14.6 **Survival of Obligations:** These obligations of confidentiality survive termination of this Agreement and continue for a period of five years after completion of the study and marketing of the DEVICE.

14.7 **Return of Confidential Information:** If requested by the Sponsor/CRO in writing, Investigator will return all Confidential Information except that required to be retained at the Study site by law. However, Investigator may retain a single archival copy of the Confidential Information for the sole purpose of determining the scope of obligations incurred under this Agreement.

15. **Study Data and Study Records:**

15.1 **Study Data:** During the course of the Study, Investigator will collect and submit certain data to the Sponsor/CRO, as specified in the Protocol. This may include case report forms or their equivalent ("Case Report Forms"), or other types of medical images, X-RAY, or other types of tracings or printouts, data summaries, or any combination of these (collectively, "Study Data"). Investigator will ensure accurate and timely collection, recording, and submission of Study Data. Investigator will deliver Study Data to the Sponsor /CRO within the reasonable time period.

15.1.1 **Ownership of Study Data:** Subject to Investigator's right to publish the results of the Study (see Section 18, Publications), the Sponsor/CRO is the exclusive owner of all Study Data.

15.1.2 **Non-exclusive License:** The Sponsor/CRO grants Investigator no right to use study data for any purpose including internal research and/or education purpose.

15.1.3 **Data Management and statistical Analysis:** The Sponsor /CRO shall carry out the data management and statistical analysis. The

Scanned with OKEN Scanner

Annexure A

Budget Sheet and other expenses:

Study Details	
Investigational device	Flexi OH-Short Arm Cast
Study ID	OH/SMO/01/2021
Study Title:	*A Prospective, Openlabel, Randomized, Clinical Trial Of Light Cured Limb Orthosis - FlexiOH® as Definitive Cast For Immobilization Of Forearm Fractures In Emergency Settings*
Indication	**Patients with Displaced Fracture of distal end of radius and/or ulna**
Phase:	Clinical Evaluation
Project Manager	
CRA	
PI Name	Dr. Kiran Kallaih
Site Name & Address	**Sri Siddhartha Medical College and Research Centre, B H Road Agalkote, Tumkur-572107, Karnataka, India**

The Budget and Payment Schedule will be the basis for calculating and reimbursing all Study-related costs. It is agreed that reimbursement will be prorated according to the actual work completed according to the Budget and Payment Schedule. Therefore, costs incurred for all qualified patients will be paid according to the Budget and Payment Schedule and actual work performed.

Fees for Each Evaluable Patient:

SMO- INDIA agrees to pay the Investigator/Institution (known as the Payee), **Rs. 10,500.00** as outlined in the "Site Study Budget" below for each patient that fully completes (completes all study visits and procedures as required by the Protocol) the Study (FlexiOH®). This sum is inclusive of all patient related costs as well as non-patient costs such as overhead expenses, completion of case report forms, audits, administrative costs, , staff time, pharmacy and costs for testing [for example X Ray as per protocol requirement] ,patient travel costs as per protocol. No additional payments shall be made to the Investigator or Institution if they are not outlined in the "Site Study Budget" below or preapproved by SMO - INDIA. The schedule of payments shall be as follows:

Subject to the final quarterly (every three-month) payment and subject to final reconciliation as provided below, payee shall receive one payment every three months to include remuneration for the number of visits completed by enrolled patients for the preceding three-month period. Payments will be calculated from SMO - INDIA's receipt of the associated visits' completed case

Scanned with OKEN Scanner

report forms. CRFs must be accurately and completely filled out by the Investigator or designated Institution staff prior to payment disbursement.

The final payment will be subject to a final reconciliation, meaning after (i) all patients have completed the Study, and the database has locked, (ii) all study specific queries and issues (including data queries) have been satisfactorily resolved. (iii) the site close out visit has been completed (including return of all study device), and (iv) Study records have been received by SMO - INDIA.

SMO - INDIA will reimburse Payee for local IRB/EC fees upon receipt of an invoice from the site with the original IRB/EC invoice as supporting documentation.

No payment shall be made to Payee by SMO - INDIA for any procedure or assessment that has not been performed according to substantial adherence to this Agreement, the Protocol or ICH/FDA GCP guidelines, or applicable laws and regulations, or for which acceptable documentation/approval of work has not been submitted to SMO - INDIA.

* A completed patient is defined as one who was followed for the duration of the Study (completes all study visits and procedures as required by the Protocol).

Institution and Investigator are expected to promptly invoice SMO - INDIA for all services rendered under this Agreement. No payment shall be made on any invoices submitted to SMO - INDIA more than 90 days after all Study procedures as required by the Protocol and/or this Agreement have been completed. Payment may take up to eight (8) weeks from the date of receipt of the invoice by SMO - INDIA.

All invoices shall be addressed to SMO Clinical Research (I) Pvt Ltd, #461, 11th Main, RMV Extension, Sadashivanagar, Bangalore-560080

Scanned with OKEN Scanner

Site Study Budget

Per Patient Grant				
	DAY 0- Screening and Recruitment visit	DAY 7 +3 Days	DAY 42- Week 6 +3 days	DAY 42-DAY 70 Week 6 to 10 (only in case of delayed healing)
Investigator Charge	Rs-3000.00	Rs-1500.00	Rs-2000.00	Rs-1250.00
Study Co-ordinator charge	Rs-1000.00	Rs-500.00	Rs-750.00	Rs-500.00
Total Cost	Rs-4000.00	Rs-2000.00	Rs-2750.00	Rs-1750.00

Total Budget	Rs 10,500.00 / Subject
	Rs 6,30,000.00 (60 subjects)

- This Includes Principal Investigator , study co-ordinator charges and any other Institutional Overhead Charges

Pass-through Cost

- Subject Travel Reimbursement Rs 500.00 per visit
- X-Ray-At Actuals
- Ethics committee Fees –At Actuals

Payee Details

Payee Name: Dr Sridhar. D.K.
Payee Address "Sri Sai Ranga", 6th A cross, 1st main, Hanumanthpura TumKur.
Bank Name: State bank of India, Sira branch.
Bank Account Number: 000000 64080561578.
Permanent Account Number (PAN) of Payee: BEOPS4654D.
GST Registration Number:

Scanned with OKEN Scanner